GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Total Premiums Earned

Cyclacel Pharmaceuticals (STU:UXI) Total Premiums Earned


View and export this data going back to 2010. Start your Free Trial

What is Cyclacel Pharmaceuticals Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.


Cyclacel Pharmaceuticals (STU:UXI) Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.